Practical Neurology

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Practical Neurology 2004;4:274-285; doi:10.1111/j.1474-7766.2004.00254.x
Copyright © 2004 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Day, J. N
Right arrow Search for Related Content
PubMed
Right arrow Articles by Day, J. N

Review

Cryptococcal Meningitis

Jeremy N Day

Clinical Research Fellow, Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 190 Ben Ham Tu, Quan 5, Ho Chi Minh City, Viet Nam; Email: jeremyday{at}hcm.vnn.vn

EXTRACT

INTRODUCTION

The HIV pandemic has raised the profile of Cryptococcus neoformans from an obscure yeast to the most important fungal cause of morbidity and death worldwide. Previously described as a rare cause of meningitis in the tropics, or in patients with some form of acquired immunodeficiency such as haematological malignancy or organ transplantation, cryptococcal meningitis is now a significant public health burden in developing countries. 20% of all AIDS deaths are due to cryptococcal meningitis, making it the second most common cause of death in HIV infection after tuberculosis (French et al. 2002). Moreover, despite the availability of highly active antiretroviral therapy (HAART), it continues to pose difficult management questions in the industrialized world. Questions remain for physicians regarding the optimal combination of antifungal agents, duration of treatment, accurate indicators of response to therapy, management of raised intracranial pressure, and the role of adjunctive therapies such as corticosteroids or other ...

[PDF of this article]


This article has been cited by other articles:


Home page
PNHome page
M. Connor, A. Williams, M. Macleod, and C. Smith
Vanishing diplopia: a problem case
Practical Neurology, August 1, 2007; 7(4): 268 - 271.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2004 by the BMJ Publishing Group Ltd.